2021 © Copyright - TPMG
Hospital News
Hospital News
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merckâs KEYTRUDA Met Primary Endpoint of Disease-Free Survival in Certain Patients With Muscle-Invasive Urothelial Carcinoma After Surgery
Admin -